Home › Funds › HSG Holding Ltd › LYEL

HSG Holding Ltd position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

HSG Holding Ltd reported holding 152,299 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.12% of its reported portfolio and ranking #17 among its reported holdings. HSG Holding Ltd has disclosed LYEL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)152.30K sh
Reported value held$1.49M
Portfolio Weight0.12%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How HSG Holding Ltd's LYEL position evolved

HSG Holding Ltd first disclosed a stake in LYEL in Q3 2023 at 3,045,997 shares (US$4.5M). The position peaked in Q1 2024 at 3,045,997 shares, worth US$7.4M. Across 13 filings, HSG Holding Ltd increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 152,299 shares valued at US$1.5M. Notable position changes include a 95% trim in Q2 2025 (shares rose 84% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.05M $4.48M New
Q4 2023 3.05M $6.40M Hold
Q1 2024 3.05M $7.43M Hold
Q2 2024 3.05M $5.00M Hold
Q3 2024 3.05M $3.41M Hold
Q4 2024 3.05M $1.74M Hold
Q1 2025 3.05M $1.46M Hold
Q2 2025 152.30K $1.35M Reduce
Q3 2025 152.30K $73.10K Hold
Q4 2025 152.30K $3.94M Hold
Q1 2026 152.30K $73.10K Hold
Q2 2026 152.30K $2.14M Hold
Q3 2026 152.30K $1.49M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 28 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$14.8M), Decheng Capital LLC (US$9.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has HSG Holding Ltd held LYEL?

HSG Holding Ltd has disclosed LYEL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is HSG Holding Ltd's current position in LYEL?

As of Q3 2026, HSG Holding Ltd holds 152.30K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $1.49M, representing 0.12% of its reported portfolio and ranking #17.

Has HSG Holding Ltd been buying or selling LYEL?

In the latest 13F filing (Q3 2026), HSG Holding Ltd held unchanged its position in LYEL. The position peaked in Q1 2024 at 3.05M shares.

Which other funds hold LYEL?

Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Decheng Capital LLC, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.